Svelte Medical launches Slender IDS in Europe

Svelte Medical Systems said today it initiated a select launch of its Slender sirolimus-eluting coronary stent-on-a-wire integrated delivery system in Europe.

The device incorporates Japan’s Asahi Intecc (TYO:7747) guide wire technology, specialized balloon design and a bioresorbable drug carrier from DSM Biomedical. The Slender’s all-in-one’ fixed-wire system with combined technologies allows for “precise steering” and controlled balloon growth for performing direct stenting in high-pressure post-dilations, Svelte Medical said.

“Slender IDS is a highly differentiated platform that fundamentally changes the way coronary stenting procedures are performed, and it will ultimately transform the DES landscape. We are excited to see physicians in the real-world share our enthusiasm for this novel platform,” CEO Jack Darby said in a press release.

The Slender IDS is the lowest-profile drug-eluting stent on the market, according to the New Providence, N.J.-based company.

“Slender IDS will result in a paradigm shift in interventional cardiology. Slender IDS is a platform designed to improve patient care by breaking with current interventional standards, and I am proud to be involved with this project,” Dr. Ferdinand Kiemeneij said in prepared remarks.

The company said results from its previous Direct I and II studies of the device indicated low rates of target lesion revascularization and no deaths or stent thromboses beyond 3 years.

Svelte Medical said it plans to begin enrollment for its next Direct III post-market study of the device in the 1st quarter this year, hoping to evaluate the “procedural efficiencies and 12-month clinical outcomes” of the device in real-world populations in Europe.

“Downsizing is the future of interventional cardiology, and Slender IDS is the first ultra-low profile DES. The ability to reduce catheter size without compromise to performance minimizes vascular trauma and enables use of the transradial approach, with all of its well-known clinical benefits, across broader subsets of patients. This makes for a much more pleasant patient experience,” Direct III post market study principal investigator Dr. Giovanni Amoroso of Amsterdam’s OLVG Hospital said in a prepared statement.

Svelte Medical said it plans to initiate an IDE study as it aims for U.S. premarket approval sometime this year.

The post Svelte Medical launches Slender IDS in Europe appeared first on MassDevice.

from MassDevice http://ift.tt/23cXHu6